...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Broker Meeting 23 Feb
Reply New Message
Back To Forum List View
Broker Meeting 23 Feb
6
tada
Feb 28, 2017 09:05PM
Icon president Re: Broker Meeting 23 Feb
3
SanFrancisco99
Feb 28, 2017 09:29PM

Thank you for sharing Tada! Did they mention anything about the current status of the ZEN-3694 stand alone trial? Last we heard, they had found the maximally tolerated dose for the once per day/everyday dosing, and were proceeding to a new cohort with an intermittent dosing as opposed to every day dosing. 

BearDownAZ

3 Recommendations
Re: Broker Meeting 23 Feb
3
tada
Mar 01, 2017 12:50PM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply